Last reviewed · How we verify
metronidazole IV 500 mg
At a glance
| Generic name | metronidazole IV 500 mg |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Pyrexia
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Hypokalaemia
- Anaemia
- Constipation
- Nausea
- Vomiting
- Hepatic function abnormal
- Insomnia
- Hypertension
Key clinical trials
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network (PHASE4)
- Risk Factors of Failure of Conservative Treatment in Acute Non Complicated Appendicitis
- A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (PHASE3)
- Mechanical Bowel Prep Randomized Study (NA)
- Antibiotic Prophylaxis in Metabolic Bariatric Surgery (NA)
- Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria (PHASE3)
- Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metronidazole IV 500 mg CI brief — competitive landscape report
- metronidazole IV 500 mg updates RSS · CI watch RSS
- Pfizer portfolio CI